Twelve Points Wealth Management LLC lifted its stake in shares of The Chemours Company (NYSE:CC - Free Report) by 55.8% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 122,032 shares of the specialty chemicals company's stock after buying an additional 43,707 shares during the quarter. Twelve Points Wealth Management LLC owned about 0.08% of Chemours worth $1,651,000 as of its most recent filing with the Securities & Exchange Commission.
Several other large investors also recently modified their holdings of CC. FNY Investment Advisers LLC acquired a new stake in Chemours in the 1st quarter valued at $27,000. UMB Bank n.a. grew its position in Chemours by 73.9% in the 1st quarter. UMB Bank n.a. now owns 2,231 shares of the specialty chemicals company's stock valued at $30,000 after purchasing an additional 948 shares during the period. Quadrant Capital Group LLC grew its position in Chemours by 100.4% in the 4th quarter. Quadrant Capital Group LLC now owns 2,234 shares of the specialty chemicals company's stock valued at $38,000 after purchasing an additional 1,119 shares during the period. Farther Finance Advisors LLC grew its position in Chemours by 170.7% in the 1st quarter. Farther Finance Advisors LLC now owns 2,290 shares of the specialty chemicals company's stock valued at $30,000 after purchasing an additional 1,444 shares during the period. Finally, Aster Capital Management DIFC Ltd acquired a new stake in Chemours in the 4th quarter valued at $48,000. Institutional investors and hedge funds own 76.26% of the company's stock.
Chemours Stock Performance
Shares of NYSE CC traded down $0.24 during mid-day trading on Friday, reaching $13.81. 3,892,089 shares of the company's stock were exchanged, compared to its average volume of 2,543,553. The firm has a market capitalization of $2.07 billion, a price-to-earnings ratio of 69.05 and a beta of 1.65. The Chemours Company has a 52 week low of $9.13 and a 52 week high of $25.54. The company has a debt-to-equity ratio of 7.01, a current ratio of 1.75 and a quick ratio of 0.83. The firm has a 50-day moving average price of $11.38 and a two-hundred day moving average price of $13.94.
Chemours (NYSE:CC - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The specialty chemicals company reported $0.13 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.19 by ($0.06). Chemours had a net margin of 0.54% and a return on equity of 23.82%. The firm had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.36 billion. During the same quarter in the prior year, the firm posted $0.32 earnings per share. The company's revenue was up .4% on a year-over-year basis. Analysts predict that The Chemours Company will post 2.03 EPS for the current year.
Chemours Dividend Announcement
The company also recently disclosed a dividend, which was paid on Monday, June 16th. Investors of record on Monday, May 19th were paid a $0.0875 dividend. This represents a yield of 3.17%. The ex-dividend date was Friday, May 16th. Chemours's dividend payout ratio is currently 175.00%.
Analysts Set New Price Targets
CC has been the topic of several recent analyst reports. The Goldman Sachs Group dropped their price objective on Chemours from $21.00 to $14.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 14th. Mizuho set a $15.00 price objective on Chemours in a research note on Tuesday, April 15th. UBS Group dropped their price objective on Chemours from $18.00 to $17.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Morgan Stanley dropped their price objective on Chemours from $22.00 to $15.00 and set an "equal weight" rating on the stock in a research note on Monday, May 12th. Finally, Wall Street Zen cut Chemours from a "hold" rating to a "sell" rating in a research note on Wednesday, May 21st. One investment analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $17.33.
View Our Latest Stock Analysis on CC
Insider Transactions at Chemours
In related news, CFO Shane Hostetter bought 4,450 shares of Chemours stock in a transaction on Monday, May 19th. The stock was acquired at an average price of $11.28 per share, with a total value of $50,196.00. Following the acquisition, the chief financial officer directly owned 59,694 shares of the company's stock, valued at $673,348.32. This represents a 8.06% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Damian Gumpel bought 7,822 shares of Chemours stock in a transaction on Tuesday, June 3rd. The shares were bought at an average cost of $9.95 per share, with a total value of $77,828.90. Following the acquisition, the insider directly owned 131,701 shares in the company, valued at approximately $1,310,424.95. This represents a 6.31% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased a total of 25,672 shares of company stock worth $251,573 over the last 90 days. 0.47% of the stock is currently owned by company insiders.
Chemours Company Profile
(
Free Report)
The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.
Read More

Before you consider Chemours, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemours wasn't on the list.
While Chemours currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report